Compare LNTH & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | TMDX |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | United States | United States |
| Employees | 808 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | 2015 | 2019 |
| Metric | LNTH | TMDX |
|---|---|---|
| Price | $63.42 | $136.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $74.17 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 1.1M | 835.5K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | 2.39 | ★ 2.54 |
| Revenue | ★ $1,525,933,000.00 | $566,354,000.00 |
| Revenue This Year | $0.01 | $38.84 |
| Revenue Next Year | $1.24 | $20.43 |
| P/E Ratio | ★ $26.45 | $53.83 |
| Revenue Growth | 1.95 | ★ 41.20 |
| 52 Week Low | $47.25 | $55.00 |
| 52 Week High | $111.29 | $156.00 |
| Indicator | LNTH | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 71.16 | 54.31 |
| Support Level | $57.44 | $133.50 |
| Resistance Level | $59.30 | $156.00 |
| Average True Range (ATR) | 2.14 | 8.50 |
| MACD | 0.82 | 0.41 |
| Stochastic Oscillator | 91.35 | 55.98 |
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.